Regorafenib plus aspirin then standard chemo for metastatic bowel cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding regorafenib and low-dose aspirin before standard chemotherapy can slow metastatic colorectal cancer after it has progressed on prior treatment. It may help by trying a different cancer-fighting approach earlier, followed by the usual chemo plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic colorectal cancer confirmed by pathology (a biopsy/piece of tumor)
- Your cancer has already progressed after first-line chemo, and you received one of several specific first treatments
- Your cancer must match a specific “not working” pattern (progression within 3 months, or relapse within 6 months) after that earlier treatment
- Tumor tests must show microsatellite-stable (MSS), no BRAF V600E mutation, and a known RAS status
- You must be well enough to take treatment (age 18+, and general function score of 0–1) and have measurable tumor on scans
- Your blood, kidney, and liver tests must be within required safety limits, and you must not be pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of regorafenib (a targeted pill that cuts off blood supply to tumors) with a low-dose, continuous chemotherapy regimen for people whose colorectal cancer has spread and is no longer responding to standard treatments. The goal is to see if this mix can slow or stop the cancer's growth.
This trial tests a new drug, ivonescimab, combined with chemotherapy for people whose colorectal cancer has spread to other parts of the body but not to the liver. The goal is to see if this combination works better than current treatments for this specific type of cancer.
This Phase 2 study tests whether adding TAS-102 to regorafenib works better than regorafenib by itself for metastatic colorectal cancer after at least one prior treatment has stopped working. It aims to improve how long the cancer can be controlled for patients in later treatment lines.
This trial tests a combination of a targeted therapy pill (TKI) and an immunotherapy (PD-1 inhibitor) for people with advanced colorectal cancer that has stopped responding to standard treatments. It uses a blood test to tailor the treatment, aiming to be more effective with fewer side effects.
This trial studies whether giving focused radiation (SBRT) together with fruquintinib and immune drugs (PD-1/CTLA-4) can control advanced, hard-to-remove colorectal cancer. It is for people whose cancer has grown despite standard first- and second-line chemotherapy.
This trial tests a combination of two drugs, regorafenib and 5-FU with leucovorin, for people with colorectal cancer that has spread and has not responded to at least two previous treatments. The goal is to see if this new mix can help shrink or control the cancer.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.